PitchSend

Nuvectis Pharma Investor Presentation Deck

NXP900: Phase 1a Initiated in 3Q2023 Patients with advanced solid tumors NuvectisPharma, Inc. Clinical trials.gov NCT05873686 Phase 1a Dose Escalation Starting dose of 20 mg, QD Primary Objective: Select doses/schedules for Phase 1b Key Endpoints: Assess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities 22

View entire presentation